Search research articles
Contact Us
Filters
Showing results (21-30 of 27) with videos related to
Page
of 3
Sort By:
You have reached the last page of results.
This site can display upto 27 results.
American Journal of Clinical Pathology
|
May 15, 2015
Conventional karyotyping and fluorescence in situ hybridization: an effective utilization strategy in diagnostic adult acute myeloid leukemia
Rong He, Anne E Wiktor, Curtis A Hanson, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
January 19, 2006
Preclinical validation of fluorescence in situ hybridization assays for clinical practice
Anne E Wiktor, Daniel L Van Dyke, Peggy J Stupca, et al.
American Journal of Clinical Pathology
|
January 23, 2010
Comparison of fluorescence in situ hybridization, p57 immunostaining, flow cytometry, and digital image analysis for diagnosing molar and nonmolar products of conception
Benjamin R Kipp, Rhett P Ketterling, Trynda N Oberg, et al.
Mayo Clinic Proceedings
|
September 2, 2009
Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas
Gordon W Dewald, Thomas C Smyrk, Erik C Thorland, et al.
Breast Cancer Research and Treatment
|
February 20, 2013
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
Edith A Perez, Michael F Press, Amylou C Dueck, et al.
Leukemia Research
|
May 29, 2017
Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials
Stephen A Strickland, Zhuoxin Sun, Rhett P Ketterling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2011
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial
Edith A Perez, Robert B Jenkins, Amylou C Dueck, et al.
Page
of 3
Search research articles
Search
Showing results (21-30 of 27) with videos related to
Sort By:
Page
of 3
You have reached the last page of results.
This site can display upto 27 results.
American Journal of Clinical Pathology
|
May 15, 2015
Conventional karyotyping and fluorescence in situ hybridization: an effective utilization strategy in diagnostic adult acute myeloid leukemia
Rong He, Anne E Wiktor, Curtis A Hanson, et al.
Genetics in Medicine : Official Journal of the American College of Medical Genetics
|
January 19, 2006
Preclinical validation of fluorescence in situ hybridization assays for clinical practice
Anne E Wiktor, Daniel L Van Dyke, Peggy J Stupca, et al.
American Journal of Clinical Pathology
|
January 23, 2010
Comparison of fluorescence in situ hybridization, p57 immunostaining, flow cytometry, and digital image analysis for diagnosing molar and nonmolar products of conception
Benjamin R Kipp, Rhett P Ketterling, Trynda N Oberg, et al.
Mayo Clinic Proceedings
|
September 2, 2009
Fluorescence in situ hybridization to visualize genetic abnormalities in interphase cells of acinar cell carcinoma, ductal adenocarcinoma, and islet cell carcinoma of the pancreas
Gordon W Dewald, Thomas C Smyrk, Erik C Thorland, et al.
Breast Cancer Research and Treatment
|
February 20, 2013
Immunohistochemistry and fluorescence in situ hybridization assessment of HER2 in clinical trials of adjuvant therapy for breast cancer (NCCTG N9831, BCIRG 006, and BCIRG 005)
Edith A Perez, Michael F Press, Amylou C Dueck, et al.
Leukemia Research
|
May 29, 2017
Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials
Stephen A Strickland, Zhuoxin Sun, Rhett P Ketterling, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|
January 20, 2011
C-MYC alterations and association with patient outcome in early-stage HER2-positive breast cancer from the north central cancer treatment group N9831 adjuvant trastuzumab trial
Edith A Perez, Robert B Jenkins, Amylou C Dueck, et al.
Page
of 3